Q2 2025 · 13F-HR
Ally Bridge Group (NY) LLCholdings as filed
Filed 2025-08-14 · accession 0000950123-25-008419
$120.2M
Reported value
24
Positions
2025-06-30
Period end
The Brief · Ally Bridge Group (NY) LLC · Q2 2025
AI · grounded in 13F
Ally Bridge Group (NY) LLC established a new position in VRNA valued at $15.2M. The fund also initiated new stakes in SLNO for $15.0M and LENZ for $10.1M. Other new additions include MERUS N V at $7.4M and ULTRAGENYX PHARMACEUTICAL IN at $5.8M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 925050106 | VRNA | VERONA PHARMA PLC | $15.2M | 12.6% | 160,701 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $15.0M | 12.5% | 178,819 | Common | SOLE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $10.1M | 8.37% | 343,322 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $7.4M | 6.14% | 140,208 | Common | SOLE |
| 90400D908 | — | ULTRAGENYX PHARMACEUTICAL IN | $5.8M | 4.84% | 1,600 | Common | NONE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $5.6M | 4.70% | 281,394 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $4.9M | 4.10% | 485,629 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $4.9M | 4.09% | 528,491 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $4.9M | 4.08% | 121,182 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $4.8M | 4.00% | 47,710 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $4.7M | 3.92% | 726,172 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $4.6M | 3.81% | 3,251,475 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $4.2M | 3.46% | 1,485,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $3.9M | 3.21% | 293,986 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $3.8M | 3.14% | 132,744 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $3.5M | 2.93% | 724,000 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $3.5M | 2.90% | 867,302 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $3.4M | 2.83% | 80,880 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $3.3M | 2.71% | 163,683 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $1.9M | 1.60% | 154,223 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $1.5M | 1.27% | 817,939 | Common | SOLE |
| 002120202 | ATYR | ATYR PHARMA INC | $1.5M | 1.21% | 287,720 | Common | SOLE |
| 61023L207 | MNPR | MONOPAR THERAPEUTICS INC | $1.2M | 1.03% | 34,537 | Common | SOLE |
| 74346M406 | PMNEUR | PROMIS NEUROSCIENCES INC | $645,596 | 0.54% | 1,334,428 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.